Olive exaggerates cost savings; Happify Health reports DTx curbs anxiety in psoriasis patients; and other digital health briefs

Axios’  Erin Brodwin published a new investigation which found out health care automation startup Olive is exaggerating its abilities and only works by using “rough estimations” to gauge its charge price savings. In accordance to the report, Olive, which claims health techniques expense financial savings, is only tracking financial savings if a customer requests it. The report also highlighted Olive employees’ worries about how the company handles client wellbeing details. 

This report will come much less than a 12 months right after the business shut a whopping $400 million financial commitment round, which introduced its valuation to $4 billion. 

---

Digital therapeutic company Happify unveiled final results of its true-entire world psoriasis details assessment. Researchers found that clients with psoriasis who accomplished 16 Happify routines within a minimum of six weeks described a 27% reduction in anxiety indicators and a 27% raise in subjective wellbeing.

Meanwhile, the study reports that men and women who completed fewer than 16 activities enhanced their wellbeing rating by 4.11% and lowered their anxiousness score by 8.15%. 

The investigation was conducted by Happify Health and is not nevertheless printed in an academic journal.

---

Oura, maker of a ring wellbeing-tracking wearable, introduced earlier this week its valuation had arrived at $2.55 billion. 

Nevertheless the company did not launch even more particulars, a spokesperson explained to MobiHealthNews it experienced elevated an “oversubscribed” funding round. Oura claimed the new financial investment will go towards analysis and development, personalised articles and product innovation.

The startup most lately scooped up $100 million in Collection C funding in May 2021. 

Oura revealed its Oura Ring Technology 3 in October. The wearable maker said workout coronary heart level checking, blood-oxygen sensing and an enhanced slumber algorithm will be extra to the new wearable later in 2022. 

---

Electronic pharmacy and telehealth startup Truepill is partnering with COVID-19 testing business Curative to give clients obtain to Truepill’s COVID-19 digital care platform.

When a shopper assessments positive at one of Curative’s screening web pages, they can get telehealth consults and antiviral drugs through the platform if eligible. Truepill declared its COVID-19-focused virtual care offering in early December. 

This is not Truepill’s only digital software aimed at controlling the pandemic. In January, it introduced a test protection platform to aid payers in producing their have immediate-to-client test-getting internet sites, with Truepill fulfilling and delivery orders. In March 2021, the enterprise rolled out a suite of diagnostics, medicine delivery and get hold of-tracing instruments for the employer market. 

“Access, speed and scale are necessary to any COVID-19 response, and this is specifically true when it will come to the distribution of antiviral prescription drugs,” Truepill CEO and cofounder Sid Viswanathan reported in a assertion.

“We’re thrilled to associate with diagnostic tests chief Curative to supply an stop-to-finish, white-labeled virtual care encounter that allows productive, streamlined access to treatment.”